132 related articles for article (PubMed ID: 20147743)
1. FGFR4 Arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer.
Marmé F; Werft W; Benner A; Burwinkel B; Sinn P; Sohn C; Lichter P; Hahn M; Schneeweiss A
Ann Oncol; 2010 Aug; 21(8):1636-1642. PubMed ID: 20147743
[TBL] [Abstract][Full Text] [Related]
2. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.
Thussbas C; Nahrig J; Streit S; Bange J; Kriner M; Kates R; Ulm K; Kiechle M; Hoefler H; Ullrich A; Harbeck N
J Clin Oncol; 2006 Aug; 24(23):3747-55. PubMed ID: 16822847
[TBL] [Abstract][Full Text] [Related]
3. CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer.
Marmé F; Werft W; Walter A; Keller S; Wang X; Benner A; Burwinkel B; Sinn P; Hug S; Sohn C; Bretz N; Moldenhauer G; Rupp C; Rupp AK; Biakhov MY; Bottini A; Friedrichs K; Khailenko VA; Manikhas GM; Ruiz A; Sánchez-Rovira P; Santoro A; Segui MA; Villena C; Lichter P; Kristiansen G; Altevogt P; Schneeweiss A
Breast Cancer Res Treat; 2012 Apr; 132(3):819-31. PubMed ID: 21960110
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer.
Marmé F; Hielscher T; Hug S; Bondong S; Zeillinger R; Castillo-Tong DC; Sehouli J; Braicu I; Vergote I; Isabella C; Mahner S; Ferschke I; Rom J; Sohn C; Schneeweiss A; Altevogt P
Int J Cancer; 2012 Aug; 131(4):E586-91. PubMed ID: 22034009
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Role of the FGFR4-388Arg Variant in Lung Squamous-Cell Carcinoma Patients With Lymph Node Involvement.
Quintanal-Villalonga Á; Carranza-Carranza A; Meléndez R; Ferrer I; Molina-Pinelo S; Paz-Ares L
Clin Lung Cancer; 2017 Nov; 18(6):667-674.e1. PubMed ID: 28583379
[TBL] [Abstract][Full Text] [Related]
6.
Cho SH; Hong CS; Kim HN; Shin MH; Kim KR; Shim HJ; Hwang JE; Bae WK; Chung IJ
Cancer Res Treat; 2017 Jul; 49(3):766-777. PubMed ID: 27857023
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer.
Schneeweiss A; Marmé F; Ruiz A; Manikhas AG; Bottini A; Wolf M; Sinn HP; Mansouri K; Kennedy L; Bauknecht T
Ann Oncol; 2011 Mar; 22(3):609-617. PubMed ID: 20732932
[TBL] [Abstract][Full Text] [Related]
8. The fibroblast growth factor receptor-4 Arg388 allele is associated with gastric cancer progression.
Ye Y; Shi Y; Zhou Y; Du C; Wang C; Zhan H; Zheng B; Cao X; Sun MH; Fu H
Ann Surg Oncol; 2010 Dec; 17(12):3354-61. PubMed ID: 20844967
[TBL] [Abstract][Full Text] [Related]
9. FGFR4 Gly388Arg Polymorphism Affects the Progression of Gastric Cancer by Activating STAT3 Pathway to Induce Epithelial to Mesenchymal Transition.
Ye Y; Li J; Jiang D; Li J; Xiao C; Li Y; Han C; Zhao C
Cancer Res Treat; 2020 Oct; 52(4):1162-1177. PubMed ID: 32599983
[TBL] [Abstract][Full Text] [Related]
10. FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients.
Streit S; Mestel DS; Schmidt M; Ullrich A; Berking C
Br J Cancer; 2006 Jun; 94(12):1879-86. PubMed ID: 16721364
[TBL] [Abstract][Full Text] [Related]
11. Effects of FGFR gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-docetaxel-based chemotherapy in breast cancer patients.
Chen L; Qi H; Zhang L; Li H; Shao J; Chen H; Zhong M; Shi X; Ye T; Li Q
BMC Cancer; 2018 Oct; 18(1):1038. PubMed ID: 30359238
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor receptor 4 mutation and polymorphism in Japanese lung cancer.
Sasaki H; Okuda K; Kawano O; Yukiue H; Yano M; Fujii Y
Oncol Rep; 2008 Nov; 20(5):1125-30. PubMed ID: 18949411
[TBL] [Abstract][Full Text] [Related]
13. Prognostic implications of fibroblast growth factor receptor 4 polymorphisms in primary breast cancer.
Wei W; You Z; Sun S; Wang Y; Zhang X; Pang D; Jiang Y
Mol Carcinog; 2018 Aug; 57(8):988-996. PubMed ID: 29603419
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin/pemetrexed followed by docetaxel versus doxorubicin/ cyclophosphamide followed by docetaxel as neoadjuvant treatment for early-stage breast cancer: a randomized phase II trial.
Schneeweiss A; Lauschner I; Ruiz A; Guerrero A; Sánchez-Rovira P; Seguí MA; Goerke K; Wolf M; Manikhas AG; Wacker J; Marmé F; Lichter P; Sinn HP; Sohn C; Mansouri K; Bauknecht T; Hahn M
Clin Breast Cancer; 2007 Apr; 7(7):555-8. PubMed ID: 17509164
[TBL] [Abstract][Full Text] [Related]
15. CD24 polymorphisms cannot predict pathologic complete response to anthracycline- and taxane-based neoadjuvant chemotherapy in breast cancer.
Zhou X
Clin Breast Cancer; 2014 Apr; 14(2):e33-40. PubMed ID: 24393851
[TBL] [Abstract][Full Text] [Related]
16. Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy.
Schneider J; Gonzalez-Roces S; Pollán M; Lucas R; Tejerina A; Martin M; Alba A
Breast Cancer Res; 2001; 3(3):183-91. PubMed ID: 11305953
[TBL] [Abstract][Full Text] [Related]
17. A Polymorphism in the FGFR4 Gene Is Associated With Risk of Neuroblastoma and Altered Receptor Degradation.
Whittle SB; Reyes S; Du M; Gireud M; Zhang L; Woodfield SE; Ittmann M; Scheurer ME; Bean AJ; Zage PE
J Pediatr Hematol Oncol; 2016 Mar; 38(2):131-8. PubMed ID: 26840079
[TBL] [Abstract][Full Text] [Related]
18. Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience.
Singh JC; Mamtani A; Barrio A; Morrow M; Sugarman S; Jones LW; Yu AF; Argolo D; Smyth LM; Modi S; Schweber S; Boafo C; Patil S; Norton L; Baselga J; Hudis CA; Dang C
Oncologist; 2017 Feb; 22(2):139-143. PubMed ID: 28167568
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group.
von Minckwitz G; Raab G; Caputo A; Schütte M; Hilfrich J; Blohmer JU; Gerber B; Costa SD; Merkle E; Eidtmann H; Lampe D; Jackisch C; du Bois A; Kaufmann M
J Clin Oncol; 2005 Apr; 23(12):2676-85. PubMed ID: 15837982
[TBL] [Abstract][Full Text] [Related]
20. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer.
Diéras V; Fumoleau P; Romieu G; Tubiana-Hulin M; Namer M; Mauriac L; Guastalla JP; Pujade-Lauraine E; Kerbrat P; Maillart P; Pénault-Llorca F; Buyse M; Pouillart P
J Clin Oncol; 2004 Dec; 22(24):4958-65. PubMed ID: 15611510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
